230 related articles for article (PubMed ID: 34279417)
1. Efficacy of a Covalent Microtubule Stabilizer in Taxane-Resistant Ovarian Cancer Models.
Yee SS; Risinger AL
Molecules; 2021 Jul; 26(13):. PubMed ID: 34279417
[TBL] [Abstract][Full Text] [Related]
2. Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity.
Risinger AL; Li J; Bennett MJ; Rohena CC; Peng J; Schriemer DC; Mooberry SL
Cancer Res; 2013 Nov; 73(22):6780-92. PubMed ID: 24048820
[TBL] [Abstract][Full Text] [Related]
3. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.
Vivas-Mejia PE; Rodriguez-Aguayo C; Han HD; Shahzad MM; Valiyeva F; Shibayama M; Chavez-Reyes A; Sood AK; Lopez-Berestein G
Clin Cancer Res; 2011 Jun; 17(11):3716-26. PubMed ID: 21512144
[TBL] [Abstract][Full Text] [Related]
4. Taccalonolide microtubule stabilizers.
Li J; Risinger AL; Mooberry SL
Bioorg Med Chem; 2014 Sep; 22(18):5091-6. PubMed ID: 24491636
[TBL] [Abstract][Full Text] [Related]
5. FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression.
Heuer TS; Ventura R; Mordec K; Lai J; Fridlib M; Buckley D; Kemble G
EBioMedicine; 2017 Feb; 16():51-62. PubMed ID: 28159572
[TBL] [Abstract][Full Text] [Related]
6. Identification of C-6 as a New Site for Linker Conjugation to the Taccalonolide Microtubule Stabilizers.
Du L; Risinger AL; Yee SS; Ola ARB; Zammiello CL; Cichewicz RH; Mooberry SL
J Nat Prod; 2019 Mar; 82(3):583-588. PubMed ID: 30799622
[TBL] [Abstract][Full Text] [Related]
7. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
[TBL] [Abstract][Full Text] [Related]
8. Lx2-32c, a novel taxane derivative, exerts anti-resistance activity by initiating intrinsic apoptosis pathway in vitro and inhibits the growth of resistant tumor in vivo.
Zhou Q; Li Y; Jin J; Lang L; Zhu Z; Fang W; Chen X
Biol Pharm Bull; 2012; 35(12):2170-9. PubMed ID: 23207769
[TBL] [Abstract][Full Text] [Related]
9. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
11. Cellular studies reveal mechanistic differences between taccalonolide A and paclitaxel.
Risinger AL; Mooberry SL
Cell Cycle; 2011 Jul; 10(13):2162-71. PubMed ID: 21597323
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
13. CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
Pabla N; Sparreboom A
Clin Cancer Res; 2015 Mar; 21(6):1237-9. PubMed ID: 25770292
[TBL] [Abstract][Full Text] [Related]
14. Taccalonolide Microtubule Stabilizers.
Yee SS; Du L; Risinger AL
Prog Chem Org Nat Prod; 2020; 112():183-206. PubMed ID: 33306174
[TBL] [Abstract][Full Text] [Related]
15. Ixabepilone: a new microtubule-targeting agent for breast cancer.
Higa GM; Abraham J
Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
[TBL] [Abstract][Full Text] [Related]
16. Smoothened antagonists reverse taxane resistance in ovarian cancer.
Steg AD; Katre AA; Bevis KS; Ziebarth A; Dobbin ZC; Shah MM; Alvarez RD; Landen CN
Mol Cancer Ther; 2012 Jul; 11(7):1587-97. PubMed ID: 22553355
[TBL] [Abstract][Full Text] [Related]
17. Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.
Wang R; Wang H; Wang Z
J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287508
[TBL] [Abstract][Full Text] [Related]
18. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.
Darshan MS; Loftus MS; Thadani-Mulero M; Levy BP; Escuin D; Zhou XK; Gjyrezi A; Chanel-Vos C; Shen R; Tagawa ST; Bander NH; Nanus DM; Giannakakou P
Cancer Res; 2011 Sep; 71(18):6019-29. PubMed ID: 21799031
[TBL] [Abstract][Full Text] [Related]
19. Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.
Levy A; Alhazzani K; Dondapati P; Alaseem A; Cheema K; Thallapureddy K; Kaur P; Alobid S; Rathinavelu A
Curr Cancer Drug Targets; 2019; 19(3):179-188. PubMed ID: 29984656
[TBL] [Abstract][Full Text] [Related]
20. Mechanical aspects of microtubule bundling in taxane-treated circulating tumor cells.
Kim M; Rejniak KA
Biophys J; 2014 Sep; 107(5):1236-1246. PubMed ID: 25185559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
